April 25, 2025 11:09 AM EDT
R&D

Hop­ing to turn CD47 around with Keytru­da com­bo, ALX On­col­o­gy re­ports two Phase 2 fail­ures

Max Gelman

Senior Editor

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump.

The com­pa­ny said Fri­day that two tri­als test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

Mer­ck cuts sev­er­al Phase 2 pro­grams; Vyne’s Phase 1b pso­ri­a­sis tri­al put on clin­i­cal hold

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times